Syros Pharmaceuticals, Inc. (SYRS)
US — Healthcare Sector
Automate Your Wheel Strategy on SYRS
With Tiblio's Option Bot, you can configure your own wheel strategy including SYRS - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol SYRS
- Rev/Share 0.0098
- Book/Share -0.2832
- PB -0.1087
- Debt/Equity -5.4145
- CurrentRatio 2.2517
- ROIC -2.0117
- MktCap 826441.0
- FreeCF/Share -2.548
- PFCF -0.0083
- PE -0.0124
- Debt/Assets 0.7086
- DivYield 0
- ROE -27.4684
- Rating B-
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 5
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
About Syros Pharmaceuticals, Inc. (SYRS)
- IPO Date 2016-06-30
- Website https://www.syros.com
- Industry Biotechnology
- CEO Dr. James E. Bradner M.D.
- Employees 68
Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatments for cancer and monogenic diseases, and building a pipeline of gene control medicines. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors. It has target discovery, research collaboration, and option agreement with Incyte Corporation to identify therapeutic targets with a focus on myeloproliferative neoplasms; and a license agreement with TMRC Co. Ltd. for the development and commercialization of tamibarotene. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Cambridge, Massachusetts.